Mark J Roschewski, M.D.
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mark J Roschewski, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:33 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04933617 · Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell LymphomasNational Cancer Institute (NCI) · terminated · Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma · principal investigator
- Ph1NCT04599634 · Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesNational Cancer Institute (NCI) · completed · Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma · principal investigator
- Ph2NCT03255018 · Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell LymphomasNational Cancer Institute (NCI) · completed · Non-Hodgkin Lymphoma, Lymphoma, Diffuse Large B-Cell Lymphoma · principal investigator
- Ph2NCT01248455 · A Phase II Trial of Anti-KIR in Smoldering Multiple MyelomaNational Cancer Institute (NCI) · terminated · Multiple Myeloma, Myeloma, Smoldering Multiple Myeloma · principal investigator
- N/ANCT01109407 · Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)National Cancer Institute (NCI) · terminated · Smoldering Myeloma, Monoclonal Gammopathy of Undetermined Significance · principal investigator
- Ph2NCT01092182 · Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell LymphomaNational Cancer Institute (NCI) · completed · Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma · principal investigator
- Ph1NCT00861510 · A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid MalignanciesNational Heart, Lung, and Blood Institute (NHLBI) · completed · Lymphoma, Mantle-cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Hairy Cell · principal investigator
- Ph2NCT00001337 · Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's LymphomaNational Cancer Institute (NCI) · completed · Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.